WO1997047734A1 - Differenciation et culture in vitro de cellules souches multipotentes de primates et usages therapeutiques - Google Patents
Differenciation et culture in vitro de cellules souches multipotentes de primates et usages therapeutiques Download PDFInfo
- Publication number
- WO1997047734A1 WO1997047734A1 PCT/US1997/010316 US9710316W WO9747734A1 WO 1997047734 A1 WO1997047734 A1 WO 1997047734A1 US 9710316 W US9710316 W US 9710316W WO 9747734 A1 WO9747734 A1 WO 9747734A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- stem cells
- medium
- pluripotent stem
- culture
- Prior art date
Links
- 210000001778 pluripotent stem cell Anatomy 0.000 title claims abstract description 48
- 241000288906 Primates Species 0.000 title claims abstract description 28
- 238000000338 in vitro Methods 0.000 title abstract description 8
- 238000009795 derivation Methods 0.000 title description 21
- 230000001225 therapeutic effect Effects 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 31
- 238000011282 treatment Methods 0.000 claims abstract description 16
- 230000000694 effects Effects 0.000 claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 180
- 239000003102 growth factor Substances 0.000 claims description 56
- 210000002459 blastocyst Anatomy 0.000 claims description 32
- 108090000623 proteins and genes Proteins 0.000 claims description 30
- 210000002966 serum Anatomy 0.000 claims description 28
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 102000004058 Leukemia inhibitory factor Human genes 0.000 claims description 13
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims description 13
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 12
- 238000012423 maintenance Methods 0.000 claims description 12
- 239000003797 essential amino acid Substances 0.000 claims description 11
- 235000020776 essential amino acid Nutrition 0.000 claims description 11
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 10
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 10
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims description 7
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims description 7
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 7
- 108010088751 Albumins Proteins 0.000 claims description 6
- 102000009027 Albumins Human genes 0.000 claims description 6
- 102000004877 Insulin Human genes 0.000 claims description 6
- 108090001061 Insulin Proteins 0.000 claims description 6
- 229940125396 insulin Drugs 0.000 claims description 6
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 5
- 102000004889 Interleukin-6 Human genes 0.000 claims description 4
- 108090001005 Interleukin-6 Proteins 0.000 claims description 4
- 108090000630 Oncostatin M Proteins 0.000 claims description 4
- 102000004140 Oncostatin M Human genes 0.000 claims description 4
- 108010039445 Stem Cell Factor Proteins 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- -1 transferr Proteins 0.000 claims description 4
- 230000009089 cytolysis Effects 0.000 claims description 3
- 210000000143 trophectoderm cell Anatomy 0.000 claims description 3
- 102000010781 Interleukin-6 Receptors Human genes 0.000 claims description 2
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims description 2
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims description 2
- 238000012606 in vitro cell culture Methods 0.000 claims 3
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 102000015215 Stem Cell Factor Human genes 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 abstract description 33
- 210000002257 embryonic structure Anatomy 0.000 abstract description 23
- 238000011161 development Methods 0.000 abstract description 12
- 238000003556 assay Methods 0.000 abstract description 4
- 208000026350 Inborn Genetic disease Diseases 0.000 abstract description 3
- 208000016361 genetic disease Diseases 0.000 abstract description 3
- 230000001902 propagating effect Effects 0.000 abstract description 3
- 230000002068 genetic effect Effects 0.000 abstract description 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract description 2
- 230000004069 differentiation Effects 0.000 description 43
- 239000002609 medium Substances 0.000 description 36
- 201000010099 disease Diseases 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 210000001161 mammalian embryo Anatomy 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 11
- 102000001301 EGF receptor Human genes 0.000 description 10
- 108060006698 EGF receptor Proteins 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 9
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 9
- 210000002950 fibroblast Anatomy 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 8
- 229940126864 fibroblast growth factor Drugs 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 6
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 5
- 101800003838 Epidermal growth factor Proteins 0.000 description 5
- 102000004338 Transferrin Human genes 0.000 description 5
- 108090000901 Transferrin Proteins 0.000 description 5
- 230000024245 cell differentiation Effects 0.000 description 5
- 230000001276 controlling effect Effects 0.000 description 5
- 229940116977 epidermal growth factor Drugs 0.000 description 5
- 230000001605 fetal effect Effects 0.000 description 5
- 210000004602 germ cell Anatomy 0.000 description 5
- 239000012581 transferrin Substances 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 101150021185 FGF gene Proteins 0.000 description 4
- 108091008794 FGF receptors Proteins 0.000 description 4
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 4
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000012888 bovine serum Substances 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 210000001654 germ layer Anatomy 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 239000012679 serum free medium Substances 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 102000004266 Collagen Type IV Human genes 0.000 description 3
- 108010042086 Collagen Type IV Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 3
- 102000009465 Growth Factor Receptors Human genes 0.000 description 3
- 108010009202 Growth Factor Receptors Proteins 0.000 description 3
- 102100020880 Kit ligand Human genes 0.000 description 3
- 108010085895 Laminin Proteins 0.000 description 3
- 102000007547 Laminin Human genes 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 210000003716 mesoderm Anatomy 0.000 description 3
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 description 2
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 2
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 2
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 2
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 2
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 2
- 102100037362 Fibronectin Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 102000018120 Recombinases Human genes 0.000 description 2
- 108010091086 Recombinases Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102100035140 Vitronectin Human genes 0.000 description 2
- 108010031318 Vitronectin Proteins 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 230000000779 depleting effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000004039 endoderm cell Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000010363 gene targeting Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 102000046645 human LIF Human genes 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000036457 multidrug resistance Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003094 perturbing effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000012090 serum-supplement Substances 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 102000027257 transmembrane receptors Human genes 0.000 description 2
- 108091008578 transmembrane receptors Proteins 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102100038778 Amphiregulin Human genes 0.000 description 1
- 108010033760 Amphiregulin Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 241001146702 Candidatus Entotheonella factor Species 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 229920002157 Cellulin Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101800000155 Epiregulin Proteins 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000378 Fibroblast growth factor 3 Proteins 0.000 description 1
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 description 1
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 description 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 1
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 description 1
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 description 1
- 108090000382 Fibroblast growth factor 6 Proteins 0.000 description 1
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 description 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 1
- 102000003956 Fibroblast growth factor 8 Human genes 0.000 description 1
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 description 1
- 108090000367 Fibroblast growth factor 9 Proteins 0.000 description 1
- 102100037665 Fibroblast growth factor 9 Human genes 0.000 description 1
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 1
- 101000871708 Homo sapiens Proheparin-binding EGF-like growth factor Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 101710127797 Macrophage colony-stimulating factor 1 Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100369076 Mus musculus Tdgf1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000282576 Pan paniscus Species 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000288935 Platyrrhini Species 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100025498 Proepiregulin Human genes 0.000 description 1
- 102100033762 Proheparin-binding EGF-like growth factor Human genes 0.000 description 1
- 102100032350 Protransforming growth factor alpha Human genes 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 241000168914 Strepsirrhini Species 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000009628 adenosine deaminase deficiency Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000003322 aneuploid effect Effects 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 description 1
- 208000005980 beta thalassemia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 210000001705 ectoderm cell Anatomy 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000002219 extraembryonic membrane Anatomy 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007045 gastrulation Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000001704 mesoblast Anatomy 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002052 molecular layer Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000023895 stem cell maintenance Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- FRGKKTITADJNOE-UHFFFAOYSA-N sulfanyloxyethane Chemical compound CCOS FRGKKTITADJNOE-UHFFFAOYSA-N 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 210000000242 supportive cell Anatomy 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/235—Leukemia inhibitory factor [LIF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/237—Oncostatin M [OSM]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/33—Insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
Definitions
- the field is isolation and culture of primate pluripotent stem cells.
- Embryonic stem (ES) cells are derived from preimplantation embryos and from cultured primordial germ cells (for reviews, see, Joyner (1993) Gene Targeting, a Practical Approach, Oxford University Press: Oxford; Donovan (1994) Curr. Top. Dev. Biol. 29:189-225).
- ES cell lines have the remarkable capacity to proliferate in culture without loss of their euploid chromosomal complement and to maintain pluripotency. When they are combined with a preimplantation embryo to form a chimera, ES cells resume normal development and are capable of contributing to all tissues within an organism, including the germ line, (Joyner (1993) supra; Pedersen et al.
- the human embryo develops from a group of undifferentiated cells into an organism with many specialized cells, tissues, and organs. During embryogenesis, the fates of cells becomes gradually restricted as they enter new developmental pathways. The fate of the inner cell mass (ICM) and trophectoderm has been described for the mouse (Gardner and Papaioannou (1975) in Early Development of Mammals, Cambridge University Press, Cambridge, pp. 107-132) . This study found that the entire fetus and extra-embryonic mesoderm is formed from the non-endoderm cells of the ICM. The ICM of the primate blastocyst contains undifferentiated non-committed cells with the potential to enter a full range of developmental pathways. As these cells differentiate, they lose the capacity to enter developmental pathways that were previously open to them (Anderson (1992) Anim. Biotechnol. 3:165-175) .
- Embryonic stem cells derived from preimplantation embryos (Martin (1981) Proc. Natl. Acad. Sci. 78:7634-7638; Evans & Kaufman (1981) Nature 292:154-156) and embryonic germ (EG) cells, derived from fetal germ cells (Matsui et al .
- human and mouse embryos differ in the timing of embryonic genome expression (Braude et al. (1988) Nature 332:459-461), in the structure and function of the fetal membranes and placenta (Benirscheke & Kaufmann (1990) Pathology of the Human Placenta, Springer, New York) , and in formation of an embryonic disc instead of an egg cylinder.
- EC cells Human embryonal carcinoma (EC) cells, which are pluripotent, immortal stem cells from teratocarcinomas, have been induced to differentiate in culture (Andrews et al. (1984) Lab. Invest. 50:147-162), resulting in loss of specific cell surface markers and the appearance of new markers.
- the range of differentiation obtained from human EC cell lines is more limited than that obtained from mouse ES cells, and varies widely between cell lines (Pera et al. (1987) Int. J. Cancer 40:334-343) . All pluripotent human EC cell lines derived to date are aneuploid (Roach et al. (1993) Eur. Urol. 23:82-88, suggesting that EC cells do not provide an accurate representation of normal differentiation.
- Inner cell mass-derived cells were isolated and grown through two passages with the use of a human oviductal epithelial feeder layer in the presence of human leukemia inhibitory factor (LIF) .
- LIF human leukemia inhibitory factor
- pluripotent stem cells differentiate into intermediate progenitor cell populations of a variety of cell types, including, hematopoietic, nervous system, muscle, and endodermal cells, through in vitro induction.
- the present invention describes methods for maintaining primate pluripotent stem cells in culture, and for controlling and directing the differentiation of such cells into a variety of cell types.
- One aspect of the invention is a method for deriving passagable pluripotent stem cells from early embryos by a) growing an early primate embryo to the blastocyst stage under in vi tro culture conditions in which the developmental potential of pluripotent stem cells is maintained; b) culturing blastocyst stage embryos on feeder cell layers of fibroblasts under conditions wherein cultured pluripotent cells are derived; and c) transferring the derived cells for propagation as secondary cultures.
- such in vi tro cultures utilize medium containing essential and non-essential amino acids and a defined protein source (which may include transferrin, insulin and LDL) , in the absence of serum.
- a defined protein source is one of purified human or bovine serum albumin, or purified human or bovine serum non- albumin proteins.
- An advantage of the invention is the in vi tro production of passagable human pluripotent stem cells derived from early stage embryos, which are useful for the in vi tro production of specifically desired cell types and lineages.
- Another aspect of this invention is the treatment of a primate by administering cells of the invention to the primate.
- Another aspect of the invention is an assay which exposes cells of the invention to a compound and determining the effect of the compound on development.
- An advantage of the invention is that the cells can be maintained in culture for significant periods of time.
- a feature of the invention is the cell culture medium comprised of a particular combination of ingredients.
- pluripotent stem cell include multiple pluripotent stem cells.
- stem cell or “pluripotent stem cell” which terms are used interchangeably, is meant cells that are capable of self-regeneration during propagation, and which have the capacity in vitro or in vivo to differentiate and become intermediate stem cells that further proliferate and terminally differentiate into specific lineages.
- stem cells refers to cells that have the potential for producing multiple cell types, including for example, hematopoietic, nervous system, muscle, or endodermal cells.
- embryonic stem cells undifferentiated, immortal cells capable of differentiating into derivatives of all three embryonic germ layers.
- passagable stem cell or “passagable pluripotent embryonic stem cell” which terms are used interchangeably, is meant stem cells, as described above, that have been propagated in an in vi tro culture for a period of at least about one week, or through 3 or more passages, in an isolated form, i . e . in the absence of blastocyst-derived trophectoderm cells.
- propagation is meant to cellular reproduction. Generally the phenotype of the cell is maintained through propagation, including its potential for differentiation. The term also includes propagation into cultures where the cells are induced to differentiate into a particular lineage or lineages.
- embryo By the term “early stage primate embryo” is meant a multi-cellular structure derived by cleavage divisions of the zygote before implantation into the uterus.
- embryonic germ layer is meant either endoderm, mesoderm, or ectoderm cell layers, which are formed as a result of gastrulation and which interact in the formation of the bodily tissues and organs.
- blastocyst stage is meant a hollow ball stage embryo with an outer (termed the “trophectoderm”) layer, and an inner group of pluripotent cells (termed the “inner cell mass”) .
- terminal differentiated cells cells that comprise the predominant cell type of each organ or tissue and have the morphological or biochemical properties that confer a unique identity to each tissue or organ.
- Cell culture By the term “culturing” or “cell culture” is meant the growth of embryos, cells, or tissue explants outside of the body in a tissue culture environment.
- Cell culture medium comprises salts and nutrients, e.g. essential and non- essential ammo acids; and generally exogenous proteins, either in the form of defined proteins, e.g. purified human or bovine serum albumin; purified human or bovine serum non- albumin proteins; etc . , or an undefined protein source, e.g. fetal calf serum, human serum, etc.
- intermediate ste cells stem cells that have a reduced capacity for differentiation relative to pluripotent stem cells, yet still retain the capacity for differentiation into one or more of the cell types contained within a particular tissue or organ.
- secondary culture is meant the propagation of explanted or derived cells after their initial placement in culture, demonstrating their sustained capacity for cell proliferation. The culture conditions may be the same as those used for the initial derivation, or may be altered to provide for differentiation of the cells.
- passaging is intended the process of transferring living cells, or colonies derived thereof, sequentially from one culture vessel to another with a concomitant increase in cell number.
- pluripotent stem cells By the term “derived” or “deriving” pluripotent stem cells is meant establishing the growth of ES cells in cell culture while maintaining their potential for differentiation, including self-regeneration during propagation, and capacity for further differentiation into multiple cell lineages.
- passagable pluripotent stem cells are derived in the absence of growth factors that induce differentiation, and in the presence of growth factors that maintain the cells in an undifferentiated state by restraining differentiation.
- controlling and “directing" differentiation of pluripotent stem cells is meant directing the differentiation of pluripotent stem cells into specifically desired cell lineages through the control of culture conditions, including supplementing and depleting culture medium of specific growth factors.
- growth factor is meant a molecule capable of promoting growth or differentiation of cells, either in culture or in the intact tissue, through its specific effects on a transmembrane receptor.
- Growth factors include polypeptides, such as fibroblast growth factor, and non-polypeptide factors such as retinoic acid, that also specifically influence the growth and differentiation of cells through their action on intracellular receptor molecules that specifically mediate growth-promoting or differentiative effects.
- Epidermal growth factor(s) is meant a factor that acts through an epidermal growth factor receptor.
- EGF receptors include EGF-R (HER-1), HER-2, HER-3, and HER-4.
- EGFs include epidermal growth factor, transforming growth factor ⁇ , heparin-binding epidermal growth factor, amphiregulin, heregulins, epiregulin, ⁇ -cellulin and cripto.
- fibroblast growth factor(s) is meant a factor known to act through a fibroblast growth factor receptor.
- Known FGF receptors include FGFR1, FGFR2 (including KGFR) , FGFR3, and FGFR4.
- Known FGFs include FGF-1 (acidic FGF), FGF-2 (basic FGF), FGF-3, FGF-4, FGF-5, FGF-6, FGF-7 (keratinocyte growth factor), FGF-8 (androgen-induced growth factor) , and FGF-9 (glial activating growth factor) .
- inhibitor of the function of specific growth factor or receptor is meant an agent that interferes with the biological function of a growth factor, either by interacting with the factor itself, with its receptor, or by interfering with the function of other molecules that transduce the effects of growth factor-receptor interaction.
- inducing or “induction” of differentiation is meant causing the differentiation of cultured cells through certain additions, depletions, or other modifications of their environment, so as to bring about directed changes in the morphological or biochemical properties of the cells.
- treatment means obtaining a desired pharmacologic and/or physiologic effect.
- the effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a disease and/or adverse effect attributable to the disease.
- Treatment covers any treatment of a disease in a mammal, particularly a human, and includes:
- Passagable primate pluripotential embryonic stem cells are derived and propagated in in vi tro culture. Methods are also provided for controlling the differentiation pathway of the passagable pluripotent stem cells to produce cells of a specifically desired type. These cells thus have significant clinical use in transplantation therapy for genetic disease, cancer, and other degenerative conditions, such as amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease,Alzheimer ' s disease, etc.
- primate pluripotent stem cells inculding human pluripotent stem cells
- the derived cells may be passaged as secondary cultures for propagation of the pluripotent cells, or to induce differentiation wherein intermediate stem cells or terminally differentiated, tissue-specific cells are generated.
- Components of the in vitro culture medium including nutrients, feeder layer cells, growth factors and protein source, are manipulated in order to achieve the maintenance of pluripotential capacity, or to drive the cells into differentiation.
- the culture medium and conditions are selected to optimize viability at each stage of the invention.
- the source of pluripotent stem cells is the inner cell mass of a primate blastocyst stage embryo.
- Primate species of interest include humans; apes, e.g. chimpanzees, gorillas, orangutans and bonobos; old world and new world monkeys, e.g. macaques, baboons, etc . ; and prosimians.
- human embryos are obtained by donation with informed consent from patients, e.g. undergoing m vitro fertilization as therapy for infertility. Such donations adhere to protocols for human embryo research as approved by the responsible Institutional Review Board(s) .
- the blastocysts may be grown in culture prior to isolation of the inner cell mass, or cells may be directly isolated from an m vivo derived blastocyst.
- the medium comprises simple components. Suitable medium includes Earles' medium; Hank's balanced salt solution (HBSS) ; Eagle medium,
- the medium will include essential ammo acids, at a concentration ranging from about 0.5X to 5x the standard concentration, i.e. that which is typically found in medium such as Dulbecco' s modified Eagle medium (DME) . Non-essential ammo acids are also included, at a comparable concentration.
- the initial medium will further comprise a protein source, such Synthetic Serum Substitute (Irvine Scientific Co., Irvine, CA) ; purified human or bovine serum albumin; purified human or bovine serum non- albumin proteins, e.g. LDL, transferrin, insulin, etc .
- the medium is not supplemented with a complex source of protein, i.e.
- Culture environmental components include extracellular matrix components, e.g. fibronectin, vitronectin, laminin, collagen type IV or Matrigel; low oxygen tension ( ⁇ 20%); antibiotics; and reducing agents, e.g. b-mercaptoethanol, monothioglycerol, etc.
- Pluripotent inner cell mass cells are isolated from the trophectoderm by culture outgrowth, or by selective lysis of the trophectoderm.
- the trophectoderm cells are destroyed, leaving the inner cell mass.
- the trophectoderm may be coated with a molecular layer of trinitrobenzene sulfonic acid, washing, treating with an antibody to its derivative, DNP, and then treating with active serum complement.
- the immunosurgery may also be accomplished by coating the trophectoderm with anti- species antibody (i.e. anti-human, anti-gorilla, etc . ) followed by washing and treatment with active serum complement.
- lysis is accomplished by brief treatment with a Ca ++ ionophore, e.g. A23187 at a concentration of 1-5 x 10 "5 M, to lyse the outer cells.
- Ca ++ ionophore e.g. A23187 at a concentration of 1-5 x 10 "5 M
- These processes release the inner cell mass, which is then cultured as isolated cells on a feeder cell layer, as described below.
- the intact cleavage stage embryo is placed on the feeder cell layer and allowed to attach, flatten and grow as a two-dimensional structure containing the pluripotent cells at the center of the outgrowth.
- the pluripotent cells are isolated by physical separation, e.g. by micropipet.
- the culture conditions for blastocysts and isolated inner cell mass cells are the same unless otherwise specified, herein termed "derivation medium”.
- the derivation medium comprises a complex culture medium, e.g. Dulbecco' s modified eagle medium (DME) ; RPMI; Iscove's modified Dulbecco' s medium (IMDM); etc. ; supplemented with non-essential amino acids and environmental culture conditions as previously described. It is not necessary to supplement with essential amino acids, which are already present in the medium formulation.
- a feeder layer is used.
- a number of different cells can be used as a feeder layer, e.g. fibroblasts derived human oviductal epithelium; fetal fibroblasts derived by primary culture from the same species as the embryo; buffalo rat liver cells (BRL) cells; etc .
- fibroblasts derived human oviductal epithelium fetal fibroblasts derived by primary culture from the same species as the embryo
- buffalo rat liver cells (BRL) cells etc .
- These cell layers provide non-defined components to the medium and restrain the differentiation of the pluri
- the derivation medium is deficient in differentiative growth factors, i.e. those that induce differentiation in embryonic stem cells, e.g. epidermal growth factor; fibroblast growth factor (s) and include factors known to act through an epidermal growth factor receptor, including the EGF-R (HER-1) and HER-2, HER-3, and HER-4, and/or a fibroblast growth factor receptor, including FGFR1, FGFR2 (KGFR) , FGFR3, and FGFR .
- serum-free medium is used, supplemented with defined, purified proteins, e.g. transferrin; albumin; insulin; etc . where the growth factors are absent ab initio from the medium.
- the differentiative growth factors may also be present in the medium, but blocked from exerting their biological activity through the addition of blocking agents, e.g. antibodies that interfere with the binding of the factors and their cognate receptor; or alternatively with tyrphostins that specifically interrupt the signal transduction cascade mediated by epidermal growth factor receptor, thus impairing the effect of the several growth factors that act through the EGF receptor, etc.
- the blastocyst culture medium further comprises at least one maintenance growth factor, i . e . factors that stimulate the growth of stem cells while maintaining their potential for differentiation.
- a cocktail comprising two or more maintenance growth factors may also be used.
- LIF leukemia inhibitory factor
- CSF-1 colony stimulating factor-1
- c-kit ligand steel factor
- CNTF ciliary neurotrophic factor
- the inner cell mass expands into a small cluster of pluripotent cells and their differentiated derivatives.
- These passagable pluripotent stem cells are isolated mechanically, dissociated slightly, e.g. in trypsin, EDTA, dispase collagenase, etc., and transferred to fresh feeder layers for further culture, using the conditions described for derivation medium.
- trypsin is used for passaging the cells
- the medium may be modified to include trypsin inhibitors, e.g. peptide substrates, serum, soybean trypsin inhibitor, etc.
- the passagable pluripotent embryonic stem cells thus derived have a number of uses, including differentiation into multiple cell lineages, drug screening, as a model for differentiation, etc .
- the subsequent differentiation into intermediate stem cells or terminally differentiated cells is achieved through exposure to differentiative growth factors, including erythropoiet , bone morphogenetic protem(s), epidermal growth factor(s), and fibroblast growth factor(s), and to culture environmental components including the extracellular matrix components fibronect , vitronect , laminin, and collagen type IV, low oxygen tension ( ⁇ 20° o ), and reducing agents.
- concentration of each supplemented factor or component will depend on the specific factor or component, and may be readily determined by one skilled in the art.
- fibroblast growth factor(s) is supplied in a concentration range of approximately 10-100 ng/ml.
- Such cultures may utilize medium that is depleted in stem cell maintenance growth factors, including human LIF, CNTF, CSF-1, steel factor, etc .
- the intermediate stem cells of the invention find use as therapeutic agents by transplantation to regenerate lineages of a host deficient in stem cells.
- Conditions where such therapy is used include rescuing a subject that is diseased, e.g. suffering from lymphoma, leukemia, or other neoplastic condition, and can be treated by removal or destruction of bone marrow and hematopoietic tissue by irradiation or chemotherapy, followed by engraftment with the cells of the invention.
- the cells of the invention may be used for the treatment of genetic diseases, by restoring genetic function in genetically modified somatic cells.
- diseases including, but not limited to, ⁇ -thalassemia, sickle cell anemia, adenosine deaminase deficiency, recombinase deficiency, recombinase regulatory gene deficiency, etc. may be corrected by introduction of a wild-type gene into the cells of the invention, either by homologous or random recombination.
- Other indications of gene therapy are introduction of drug resistance genes to enable the cells of the invention to have an advantage and be subject to selective pressure during chemotherapy. Suitable drug resistance genes include, but are not limited to, the gene encoding the multidrug resistance (MDR) protein.
- MDR multidrug resistance
- Diseases other than those associated with hematopoietic cells may also be treated, where the disease is related to the lack of a particular secreted product including, but not limited to, hormones, enzymes, interferon, growth factors, or the like.
- a particular secreted product including, but not limited to, hormones, enzymes, interferon, growth factors, or the like.
- inducible production of the deficient protein may be achieved, so that production of the protein will parallel natural production, even though production will be in a different cell type from the cell type that normally produces such protein. It is also possible to insert a ribozyme, antisense or other message to inhibit particular gene products or susceptibility to diseases.
- the passagable pluripotent stem cells may be frozen at liquid nitrogen temperatures and stored for long periods of time, being thawed and capable of being reused.
- the cells will usually be stored in 5% DMSO and 95% fetal calf serum.
- Once thawed, the cells may be expanded by use of growth factors or stromal cells associated with stem cell proliferation and differentiation.
- the cells may optionally be modified to have at least one non-autologous gene, as described above for use in gene therapy, and such genetically altered populations and their progeny are embraced within the scope of this invention.
- compositions comprising the cells of the invention a form suitable for administration, e.g. by injection or infusion, to a patient in need thereof, m combination with a suitable carrier medium for use in any of the foregoing treatments.
- a suitable carrier medium for use in any of the foregoing treatments.
- Dosages of the cells of the invention for pharmaceutical uses such as reconstitution of the hematopoietic system of a patient in need thereof, will vary depending on the nature of the condition to be treated and the other aspects of the patient's treatment, e.g. prior radiation or chemotherapy, or co-therapy with agents having an influence on hematopoiesis, e.g. cytok es, as well as on the purity and viability of the cell population to be administered.
- the cells of the invention are also of use as research tools in producing various lineage restricted cell lines; detecting and evaluating growth factors relevant to stem cell self-regeneration; assaying for factors associated with development; and to test drugs that modulate or affect such systems and treat or alleviate such diseases as Parkinson' s disease; to replace tissue destroyed by degenerative or autoimmune disease; e.g. b-islet cells; identifying support cells (endothelial, stromal, fibroblast) in the developing embryo that allow for growth and differentiation of various lineages, etc .
- the stem cells of the invention may be used m assays to determine either autocnne or parac ⁇ ne regulatory signals and evaluate responses to growth factor either from external or intrinsic protein sources; and to determine the activity of media, such as conditioned media, evaluate fluids for cell growth activity, involvement with differentiation into particular lineages, or the like.
- Stem cell factors may be isolated from media or cell extracts of supportive cells in which a population of the cells of the invention are growing or a supernate of a population of the cells, by separating or fractionating the fluid, e.g. chromatographically.
- the active fraction containing the desired factor is identified by measuring the growth and differentiation of stem cells in the presence and absence of such fractions, or alternatively, using comparative analysis of fluid obtained from a population of stem cells.
- cDNA libraries of the cells of the invention may be prepared and screened for genes encoding factors of interest. Growth factor or receptor genes in the cDNA libraries may optionally be amplified and identified using oligonucleotide primers based on conserved sequences within known growth factor or receptor families.
- Immortalized cells of the invention are useful as being cells that are responsive to a factor allowing for the regeneration of stem cells, e.g. in assays for survival, activation, or proliferation in the presence and absence of the putative stem cell growth or maintenance factor.
- EXAMPLES The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to establish human pluripotent stem cell lines and their induced differentiation, and are not intended to limit the scope of what the inventors regard as their invention. Unless indicated otherwise, parts are parts by weight, temperature is in degrees centigrade, and pressure is at or near atmospheric pressure. Efforts have been made to ensure accuracy with respect to numbers used (e.g., molecular weights, amounts, particular components, etc.), but some deviations may exist.
- Example 1 Establishment of Human Pluripotent Stem Cell Lines Pre-blastocvst culture conditions. Generally, embryos fertilized in vitro or retrieved from the reproductive tract at early cleavage stages are cultured to the blastocyst stage at 37°c in an atmosphere of 5% CO ? , 95% air, in a simple medium such as KSOM (See Lawitts and Biggars (1993) Meth. in Enzvm. 225:153-164) supplemented with a protein source, such as KSOM (See Lawitts and Biggars (1993) Meth. in Enzvm. 225:153-164) supplemented with a protein source, such
- Synthetic Serum Substitute (Irvine Scientific Co., Irvine, CA) , purified human or bovine serum albumin protein, purified human or bovine serum non-albumin proteins (including transferrin, LDL, insulin, etc. ) , and with essential amino acids at 0.5x-5x their concentration in Dulbecco's modified Eagles medium (DME), and non-essential amino acids at comparable concentrations (see Ho et al . (1995) Mol. Rep, and Develop. 41:232-238) .
- DME Dulbecco's modified Eagles medium
- the protein source is provided for ease of handling and the amino acids are provided as a fixed nitrogen source. Blastocyst culture conditions. When embryos reach the blastocyst stage (or at the eight cell stage for human embryos, in the event that they are available before the blastocyst stage) , they are transferred to a complex medium, such as DME.
- DME is supplemented with non-essential amino acids, 3-mercaptoethanol or monothioglycerol, nucleosides, and antibiotics as previously described (Robertson (1987) in Teratocarcmomas and Embryonic Stem Cells: A Practical Aproach, Oxford University Press, Oxford, UK, pp. 71-112) . Additional supplements include the growth factors described below under “Growth factors added during derivation and propagation of pluripotent stem cells.”
- Fibroblasts or fibroblast-like cells grown as monolayers, are instrumental in the derivation of pluripotent primate cells. Fibroblasts from a variety of sources can be used for this purpose, for example, mouse fetal or human fetal fibroblasts, or human oviductal epithelium cells.
- the feeder cells are inactivated by irradiation with 5-6,000 rads, 250 kVp, or treatment with 0.01 mg/ml mitomycin C for 3.5 h at 37oC; then they are plated, washed, and grown to confluency on gelatin or extracellular matrix-coated dishes (as described below) . The feeder layers are then used for growing the early stage embryos or secondary stem cell cultures.
- the following polypeptide growth factors are added as supplements to the DME medium during pluripotent stem cell derivation and propagation to maintain the pluripotent, undifferentiated state of the stem cells which would otherwise differentiate in their absence.
- the cytok es leukemia inhibitory factor (LIF) and ciliary neurotrophic factor (CNTF) are used at 100-10,000 U/ml.
- the cytokine macrophage colony stimulating factor 1 (CSF-1) is used to sustain the proliferation of the pluripotent stem cells and is present at a concentration of between 100-1000 U/ml.
- growth factors are oncostatin M at a concentration of from 2 to 200 ng/ml, usually about 20 ng/ l; and IL6 at a concentration of from 50 to 5000 ng/ml, usually 500 ng/ml; IL6 soluble receptor at a concentration of from 1 to 10 mg/ml, usually 5 mg/ml.
- Other factors in stem cell derivation The key novel aspect of deriving pluripotent cells from early stage primate embryos lies in restraining their spontaneous differentiation into the early lineages and embryonic germ layers during post- blastocyst culture. This is accomplished by a combination of biophysical, biochemical, and biological conditions.
- Biophysical conditions The effects of oxidative damage on the survival of pluripotent cells is restrained by maintaining cells at below ambient oxygen levels (20%), achieved by mixing nitrogen with air to achieve the necessary lower 0 ? levels (5-10%) .
- small amounts of a reducing agent are consistently maintained in the culture medium ( ⁇ -mercaptoethanol, 0.2-1.0 ppm (v/v) ; monothioglyceral) .
- the substrata on which pluripotent cells are cultured have a role in deterring differentiation of pluripotent cells. Accordingly, during derivation of pluripotent stem cells from early stage embryos, the embryos and secondary cultures are maintained on extracellular matrices, either those produced by the feeder cell layers (see below), gelatin, or purified matrix components, such as fibronectin, vitronectin, laminin, and/or collagen type IV, or MATRIGELTM (Collaborative Research, Inc.) In the latter instance, culture dishes are coated with extracellular matrix component (s) by placing a solution (20-40 ⁇ g/ml) in the dish for 2 h, then washing the dishes with saline before adding culture medium, and embryos or cells to the dishes.
- extracellular matrix component s
- Feeder layer-derived extracellular matrices are generated by culturing non-inactivated fibroblasts to confluency on dishes, then lysing the cells with Triton X-100 (0.5% v/v), and washing extensively with saline. Growth factor depletion strategies. Key to propagating primate pluripotent cells in an undifferentiated state is to deplete the growth medium of factors that induce their differentiation into intermediate stem cells or terminally-differentiated cells. In a preferred embodiment, serum-free medium is used to achieve essentially complete absence of differentiative growth factors.
- serum may be depleted of differentiation inducing substances.
- epidermal growth factor (s) and/or fibroblast growth factor (s) are depleted from the serum used in the derivation of pluripotent cells from early stage embryos. This is accomplished either by using a defined protein source (Synthetic Serum Substitute, Irvine Scientific Co.), by selecting serum types and specific lots low in these factors, or by extracting the specific growth factor from the serum.
- fibroblast growth factors are removed from serum by stirring DME medium containing 20% serum overnight in the presence of an equal volume of heparin-derivatized Sephadex beads, which bind fibroblast growth factors and remove them from the medium.
- the depletion step is repeated until the growth factor (s) are present at below threshhold levels for inducing stem cell differentiation.
- removal is accomplished by derivatizing Sephadex beads with an antibody to the growth factor, mixing beads with serum-containing medium, and repeating this treatment until the differentiation-stimulating activity is removed from the serum.
- the growth factor-depleted serum may be replaced with complete serum, e.g. 10% heat-inactivated fetal bovine serum and 10% heat-inactivated newborn calf serum, which have been quality control tested for the capacity to support the secondary culture of established embryonic stem cells. Functional deprivation strategies.
- An alternative to depleting the growth medium of differentiation-stimulating growth factors is to functionally interfere or perturb the activity of the growth factors.
- a specific function- perturbing antibody is available, the action of specific growth factors is inhibited by adding the function-perturbing antibody directly to the serum-containing medium to inactivate the factor.
- a growth factor receptor function- perturbing antibody is available, the antibody is added to the medium, thereby blocking the function of the specific growth factor receptor.
- epidermal growth factor receptor (EGF-R) transduction is interrupted by treating the cells with certain tyrphostins that are EGF-R selective tyrosine kinase inhibitors.
- EGF-R epidermal growth factor receptor
- the action of FGF signalling receptors is inhibited at specific steps of the Ras/mitogen-activated protein (MAP) kinase pathway.
- MAP Ras/mitogen-activated protein
- Feeder cell layers are prepared as described above and used as an adjunct to the defined factors that support derivation and secondary culture of pluripotent stem cells. Regarding the role of the feeder cell layers, no rigorous distinction can be made between provisions of undefined growth factors to the medium, or removal by exhaustion or adsorption of growth factors that would otherwise induce differentiation of the stem cells.
- the general method for inducing the differentiation of established pluripotent stem cells into intermediate stem cells and subsequently into terminally differentiated cells s related to the derivation strategy in that it relies on a deprivation/supplementation regimen involving specific polypeptide growth factors.
- To induce differentiation of the pluripotent stem cells it is first necessary to release the inhibition conferred by maintenance growth factors such as LIF, CNTF, etc. This is accomplished by omitting the maintenance growth factors from the culture medium. Simultaneously, exposure to one or more, but not all, polypeptide growth factors is used to induce the specific differentiation of intermediate stem cells.
- fibroblast growth factor (10-100 ng/ml) is added to induce the differentiation of mesoderm and its derivatives, such as muscle.
- Other growth factors are omitted or specifically depleted to achieve specificity of differentiation, and thus prevent induction of undesired productions (e.g., induction of the myeloid pathway by CSF-1) .
- the methods for achieving the depletions and/or functional deprivations are the same as those described above.
- Example 2 Pluripotent stem cell culture in serum-free medium.
- Murine pre-implantation embryos were tested for the outgrowth of ES cell lines, i.e. cell lines that show the same morphology and proliferation rate as ES cell lines with demonstrated germ-line capacity.
- Blastocysts were grown in Knockout-DMEMTM containing ES cell supplement serum replacement (Life technologies R&D, Grand Island, NY) . The results are shown in Table 1.
- Human pre-implantation embryos were grown in Earle's medium supplemented with essential and non-essential amino acids and with synthetic serum supplement. The embryos were then moved onto KSOM with BRL cell feeder layers supplemented with essential and non-essential amino acids and with synthetic serum supplement. After 5 to 7 days total growth past-fertilization, the blastocyst stage embryos were transferred to two different culture conditions.
- the serum-free cultures contained mouse fibroblast feeder layer cells, DME, 25 mM sodium bicarbonate, IX non- essential amino acids, 2% bovine serum albumin, 200 mg/ml transferrin, 10 mg/ml insulin, 20 mg/ml LDL, 1% penicillin/streptomycin and 7.5 x 10 "5 monothioglycerol . As maintenance growth factors, both LIF (100 U/ml) and oncostatin M (22 ng/ml) were added to the medium.
- the serum containing cultures contained DME with 10% fetal calf serum and 10% newborn calf serum and LIF at 100 U/ml. Cultures were evaluated after 5-7 days. The results are shown in Table 2, where outgrowths are defined as a blastocyst that has attached and spread in two dimensions to a feeder layer of cells and is showing cell proliferation.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Gynecology & Obstetrics (AREA)
- Biotechnology (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU33926/97A AU3392697A (en) | 1996-06-14 | 1997-06-13 | (in vitro) derivation and culture of primate pluripotent stem cells and therapeutic uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66521796A | 1996-06-14 | 1996-06-14 | |
US08/665,217 | 1996-06-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997047734A1 true WO1997047734A1 (fr) | 1997-12-18 |
Family
ID=24669212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/010316 WO1997047734A1 (fr) | 1996-06-14 | 1997-06-13 | Differenciation et culture in vitro de cellules souches multipotentes de primates et usages therapeutiques |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU3392697A (fr) |
WO (1) | WO1997047734A1 (fr) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000034525A1 (fr) * | 1998-12-09 | 2000-06-15 | Vistagen, Inc. | Typage de toxicite utilisant des corps embryoides |
US6271436B1 (en) | 1996-10-11 | 2001-08-07 | The Texas A & M University System | Cells and methods for the generation of transgenic pigs |
US6506574B1 (en) * | 2000-04-27 | 2003-01-14 | Geron Corporation | Hepatocyte lineage cells derived from pluripotent stem cells |
JP2003525625A (ja) * | 2000-03-09 | 2003-09-02 | ウィスコンシン アラムニ リサーチ ファンデーション | 霊長類の胚幹細胞の無血清培養 |
US6635802B1 (en) | 2000-01-10 | 2003-10-21 | The Texas A&M University System | Nuclear transfer using cells cultured in serum starvation media containing apoptosis inhibitors |
US6642048B2 (en) | 2000-01-11 | 2003-11-04 | Geron Corporation | Conditioned media for propagating human pluripotent stem cells |
US6887706B2 (en) | 2001-10-03 | 2005-05-03 | Wisconsin Alumni Research Foundation | Method of in vitro differentiation of transplantable neural precursor cells from primate embryonic stem cells |
US7148062B2 (en) | 2002-03-15 | 2006-12-12 | Wicell Research Institute, Inc. | Method for generating primate trophoblasts |
US7176023B2 (en) | 2001-11-02 | 2007-02-13 | Wisconsin Alumni Research Foundation | Endothelial cells derived from primate embryonic stem cells |
US7297539B2 (en) | 2000-01-11 | 2007-11-20 | Geron Corporation | Medium for growing human embryonic stem cells |
WO2008049161A1 (fr) * | 2006-10-24 | 2008-05-02 | Adelaide Research & Innovation Pty Ltd | Procédé destiné à isoler des cellules pluripotentes à partir d'un embryon pré-implantatoire dans un milieu de culture exempt de sérum animal |
US7439064B2 (en) | 2000-03-09 | 2008-10-21 | Wicell Research Institute, Inc. | Cultivation of human embryonic stem cells in the absence of feeder cells or without conditioned medium |
US7455983B2 (en) | 2000-01-11 | 2008-11-25 | Geron Corporation | Medium for growing human embryonic stem cells |
US7473555B2 (en) | 2000-04-27 | 2009-01-06 | Geron Corporation | Protocols for making hepatocytes from embryonic stem cells |
US7588937B2 (en) | 2001-10-03 | 2009-09-15 | Wisconsin Alumni Research Foundation | Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells |
US8143009B2 (en) | 2000-06-14 | 2012-03-27 | Vistagen, Inc. | Toxicity typing using liver stem cells |
US8148151B2 (en) | 2006-06-02 | 2012-04-03 | Geron Corporation | Differentiation of primate pluripotent cells to hepatocyte-lineage cells |
US8153424B2 (en) | 2001-10-03 | 2012-04-10 | Wisconsin Alumni Research Foundation | Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells |
US9074181B2 (en) | 2005-06-22 | 2015-07-07 | Asterias Biotherapeutics, Inc. | Suspension culture of human embryonic stem cells |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990001541A1 (fr) * | 1988-08-04 | 1990-02-22 | Amrad Corporation Limited | Propagation in vitro de cellules a tiges embryonnaires |
WO1995012665A1 (fr) * | 1993-11-03 | 1995-05-11 | Diacrin, Inc. | Cellules souches embryonnaires capables de se differencier en lignees cellulaires desirees |
WO1995016770A1 (fr) * | 1993-12-17 | 1995-06-22 | Abs Global, Inc. | Cellules souches embryonnaires derivees de cellules du stade preblastocyste d'ongule et leur utilisation pour produire des ongules chimeres et transgeniques clones |
US5453357A (en) * | 1992-10-08 | 1995-09-26 | Vanderbilt University | Pluripotential embryonic stem cells and methods of making same |
WO1996022362A1 (fr) * | 1995-01-20 | 1996-07-25 | Wisconsin Alumni Research Foundation | Cellules souches embryonnaires de primates |
-
1997
- 1997-06-13 AU AU33926/97A patent/AU3392697A/en not_active Abandoned
- 1997-06-13 WO PCT/US1997/010316 patent/WO1997047734A1/fr active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990001541A1 (fr) * | 1988-08-04 | 1990-02-22 | Amrad Corporation Limited | Propagation in vitro de cellules a tiges embryonnaires |
US5453357A (en) * | 1992-10-08 | 1995-09-26 | Vanderbilt University | Pluripotential embryonic stem cells and methods of making same |
WO1995012665A1 (fr) * | 1993-11-03 | 1995-05-11 | Diacrin, Inc. | Cellules souches embryonnaires capables de se differencier en lignees cellulaires desirees |
WO1995016770A1 (fr) * | 1993-12-17 | 1995-06-22 | Abs Global, Inc. | Cellules souches embryonnaires derivees de cellules du stade preblastocyste d'ongule et leur utilisation pour produire des ongules chimeres et transgeniques clones |
WO1996022362A1 (fr) * | 1995-01-20 | 1996-07-25 | Wisconsin Alumni Research Foundation | Cellules souches embryonnaires de primates |
Non-Patent Citations (3)
Title |
---|
BONGSO A ET AL: "ISOLATION AND CULTURE OF INNER CELL MASS CELLS FROM HUMAN BLASTOCYSTS", HUMAN REPRODUCTION, vol. 9, no. 11, 1994, OXFORD GB, pages 2110 - 2117, XP000613489 * |
NICHOLS J ET AL: "DERIVATION OF GERMLINE COMPETENT EMBRYONIC STEM CELLS WITH A COMBINATION OF INTERLEUKIN-6 AND SOLUBLE INTERLEUKIN-6 RECEPTOR", EXPERIMENTAL CELL RESEARCH, vol. 215, no. 1, November 1994 (1994-11-01), US, pages 237 - 239, XP002044063 * |
THOMSON J A ET AL: "ISOLATION OF A PRIMATE EMBRYONIC STEM CELL LINE", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 92, no. 17, August 1995 (1995-08-01), WASHINGTON US, pages 7844 - 7848, XP000604992 * |
Cited By (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6369294B1 (en) | 1996-10-11 | 2002-04-09 | Texas A&M University System | Methods comprising apoptosis inhibitors for the generation of transgenic pigs |
US6271436B1 (en) | 1996-10-11 | 2001-08-07 | The Texas A & M University System | Cells and methods for the generation of transgenic pigs |
US8097458B2 (en) | 1998-10-23 | 2012-01-17 | Geron Corporation | Micro-carrier culture system for rapid expansion of human embryonic stem cells |
US8951800B2 (en) | 1998-10-23 | 2015-02-10 | Asterias Biotherapeutics, Inc. | Primate pluripotent stem cell expansion without feeder cells and in the presence of FGF and matrigel or Engelbreth-Holm-Swarm tumor cell preparation |
US10059939B2 (en) | 1998-10-23 | 2018-08-28 | Asterias Biotherapeutics, Inc. | Screening methods for human embryonic stem cells |
US8637311B2 (en) | 1998-10-23 | 2014-01-28 | Asterias Biotherapeutics, Inc. | Human embryonic stem cells genetically modified to contain a nucleic acid and cultured with fibroblast growth factor |
WO2000034525A1 (fr) * | 1998-12-09 | 2000-06-15 | Vistagen, Inc. | Typage de toxicite utilisant des corps embryoides |
US6635802B1 (en) | 2000-01-10 | 2003-10-21 | The Texas A&M University System | Nuclear transfer using cells cultured in serum starvation media containing apoptosis inhibitors |
US7297539B2 (en) | 2000-01-11 | 2007-11-20 | Geron Corporation | Medium for growing human embryonic stem cells |
US7455983B2 (en) | 2000-01-11 | 2008-11-25 | Geron Corporation | Medium for growing human embryonic stem cells |
US6642048B2 (en) | 2000-01-11 | 2003-11-04 | Geron Corporation | Conditioned media for propagating human pluripotent stem cells |
US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
US7041438B2 (en) | 2000-01-11 | 2006-05-09 | Geron Corporation | Use of human embryonic stem cells for drug screening and toxicity testing |
US7005252B1 (en) | 2000-03-09 | 2006-02-28 | Wisconsin Alumni Research Foundation | Serum free cultivation of primate embryonic stem cells |
US7439064B2 (en) | 2000-03-09 | 2008-10-21 | Wicell Research Institute, Inc. | Cultivation of human embryonic stem cells in the absence of feeder cells or without conditioned medium |
JP2003525625A (ja) * | 2000-03-09 | 2003-09-02 | ウィスコンシン アラムニ リサーチ ファンデーション | 霊長類の胚幹細胞の無血清培養 |
US7473555B2 (en) | 2000-04-27 | 2009-01-06 | Geron Corporation | Protocols for making hepatocytes from embryonic stem cells |
US6506574B1 (en) * | 2000-04-27 | 2003-01-14 | Geron Corporation | Hepatocyte lineage cells derived from pluripotent stem cells |
US9587223B2 (en) | 2000-04-27 | 2017-03-07 | Asterias Biotherapeutics, Inc. | Protocols for making hepatocytes from embryonic stem cells |
EP2256187A1 (fr) | 2000-04-27 | 2010-12-01 | Geron Corporation | Cellules hépatocytes de lignée derivées de cellules souches pluripotentielles |
US8546139B2 (en) | 2000-04-27 | 2013-10-01 | Geron Corporation | Protocols for making hepatocytes from embryonic stem cells |
US8512957B2 (en) | 2000-06-14 | 2013-08-20 | Vistagen Therapeutics, Inc. | Toxicity typing using liver stem cells |
US8143009B2 (en) | 2000-06-14 | 2012-03-27 | Vistagen, Inc. | Toxicity typing using liver stem cells |
US7410798B2 (en) | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
US9080151B2 (en) | 2001-10-03 | 2015-07-14 | Wisconsin Alumni Research Foundation | Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells |
US6887706B2 (en) | 2001-10-03 | 2005-05-03 | Wisconsin Alumni Research Foundation | Method of in vitro differentiation of transplantable neural precursor cells from primate embryonic stem cells |
US7588937B2 (en) | 2001-10-03 | 2009-09-15 | Wisconsin Alumni Research Foundation | Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells |
US8153424B2 (en) | 2001-10-03 | 2012-04-10 | Wisconsin Alumni Research Foundation | Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells |
US7972850B2 (en) | 2001-10-03 | 2011-07-05 | Wisonsin Alumni Research Foundation | Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells |
US7176023B2 (en) | 2001-11-02 | 2007-02-13 | Wisconsin Alumni Research Foundation | Endothelial cells derived from primate embryonic stem cells |
US7148062B2 (en) | 2002-03-15 | 2006-12-12 | Wicell Research Institute, Inc. | Method for generating primate trophoblasts |
US10435666B2 (en) | 2002-03-15 | 2019-10-08 | Wicell Research Institute, Inc. | Method for generating primate trophoblasts |
US9074181B2 (en) | 2005-06-22 | 2015-07-07 | Asterias Biotherapeutics, Inc. | Suspension culture of human embryonic stem cells |
US10676714B2 (en) | 2005-06-22 | 2020-06-09 | Asterias Biotherapeutics, Inc. | Suspension culture of human embryonic stem cells |
US8148151B2 (en) | 2006-06-02 | 2012-04-03 | Geron Corporation | Differentiation of primate pluripotent cells to hepatocyte-lineage cells |
AU2007308746B2 (en) * | 2006-10-24 | 2014-05-08 | Icmstemcell Pty Ltd | Method for the isolation of pluripotent cells from a pre-implantation embryo in a culture medium free from animal serum |
US9499785B2 (en) | 2006-10-24 | 2016-11-22 | Icmstemcell Pty Ltd | Isolating a mammalian embryonic stem cell from a homogenous pluripotent outgrowth of a mammalian pre-implantation embryo |
WO2008049161A1 (fr) * | 2006-10-24 | 2008-05-02 | Adelaide Research & Innovation Pty Ltd | Procédé destiné à isoler des cellules pluripotentes à partir d'un embryon pré-implantatoire dans un milieu de culture exempt de sérum animal |
Also Published As
Publication number | Publication date |
---|---|
AU3392697A (en) | 1998-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11512283B2 (en) | Media for culturing stem cells | |
US10351821B2 (en) | Neural cell populations from primate pluripotent stem cells | |
WO1997047734A1 (fr) | Differenciation et culture in vitro de cellules souches multipotentes de primates et usages therapeutiques | |
US7297539B2 (en) | Medium for growing human embryonic stem cells | |
US20090311781A1 (en) | Methods of expanding embryonic stem ceels in a suspension culture | |
CA2434362A1 (fr) | Cellules souches adultes pluripotentes provenant de tissu regeneratif | |
WO2005017131A2 (fr) | Methodes pour la differenciation de cellules souches humaines | |
US20080260722A1 (en) | Method for High Efficiency Survival/Proliferation of Human Embyonic Stem Cells and Human Embryo Survival in Culture | |
Fang et al. | Stem cells and combinatorial science | |
AU2012261726B2 (en) | Media for Culturing Stem Cells | |
Schuldiner et al. | differentiation of human | |
AU2015203310A1 (en) | Media for Culturing Stem Cells | |
AU2002244652A1 (en) | Pluripotent adult stem cells derived from regenerative tissue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN YU AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 98501866 Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
122 | Ep: pct application non-entry in european phase |